Target Validation in Drug Discovery

1st Edition

Editors: Brian Metcalf Susan Dillon
Hardcover ISBN: 9780123693938
eBook ISBN: 9780080465975
Imprint: Academic Press
Published Date: 22nd September 2006
Page Count: 296
102.00 + applicable tax
83.95 + applicable tax
66.99 + applicable tax
110.00 + applicable tax
Compatible Not compatible
VitalSource PC, Mac, iPhone & iPad Amazon Kindle eReader
ePub & PDF Apple & PC desktop. Mobile devices (Apple & Android) Amazon Kindle eReader
Mobi Amazon Kindle eReader Anything else

Institutional Access


This work presents a comprehensive contemporary framework for approaching target validation in drug discovery. It begins with a detailed description of new enabling technologies, including aptamers, RNA interference, functional genomics, and proteomics. The next section looks at biologic drug development with in-depth discussion of lessons learned from such well-known cases as Erbitux, Herceptin, and Avastin. Additional targets known as "second generation" drugs, which can be identified when disease pathways are validated by biologics, present new possible small molecule therapeutics and serve as the focus of the final section of the book.


Professionals in biotechnology and pharmaceutical drug discovery and clinical development. Can also include students and academics in the related areas of study.

Table of Contents

Section Contents I. Pharmaceutical Biotechnology for Target Validation II. Target Validation for Biopharmaceutical Drug Discovery III. Validating Targets of Small Molecule Approaches


No. of pages:
© Academic Press 2007
Academic Press
eBook ISBN:
Hardcover ISBN:

About the Editor

Brian Metcalf

Affiliations and Expertise

Chief Drug Discovery Officer, Incyte Corporation, Moraga, CA, U.S.A.

Susan Dillon

Affiliations and Expertise

Senior Vice President, Discovery Research Centocor, Johnson & Johnson, Malvern, PA, U.S.A.